Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone

Onkologie

Volumn 29, Issue 12, 2006, Pages 557-561

  Oechsle, K ^a,b   Muller M R ^a   Hartmann, J T ^a   Kanz, L ^a   Bokemeyer, C ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

5 HT3 antagonist; Aprepitant; Nausea: chemotherapy induced, delayed, refractory; NK1 antagonist

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANISETRON; METOCLOPRAMIDE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENERAL CONDITION IMPROVEMENT; GERM CELL TUMOR; HODGKIN DISEASE; HUMAN; LUNG CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; SARCOMA; SOLID TUMOR; STOMACH CANCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; VISUAL ANALOG SCALE;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; RECEPTORS, SEROTONIN, 5-HT3; SALVAGE THERAPY; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 33845778940     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096689     Document Type: Article

References (20)

1. Hichok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-6.
2. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
3. Hesketh PJ: Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994;2:286-92.
4. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
5. Italian Group for Antiemetic Research: Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
6. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal, Warr D, Sheperd F, Mee D, Nishimura L, Osoba D, Zee B: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:1174-8.
7. Goedehals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C: Control of delayed nausea with granisetron plus dexamethasone or dexamethasone alone in patients with highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998;9:661-6.
8. Tavorath R, Hesketh PJ: Drug treatment of chemotherapy-induced delayed emesis. Drugs 1999;52:639-48.
9. De Wit R, Schmitz PI, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS, van der Burg ME, Stoter G: Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996;14:644-51.
10. De Wit R, van den Berg H, Burghouts J, Nortier J, Slee P, Rodenburg C, Keizer J, Fonteyn M, Verweij J, Wils J: Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998;77:1487-91.
11. Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P: Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 2001;19:2091-7.
12. Amin AH, Crawford TBB, Gaddum JH: The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J Physiol 1954;126:596-618.
13. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, Del-Prete S, Bacinsky ME, Dirlamm NL, Stack CB, Silberman SL: Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-43.
14. De Witt R: Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer 2003;86:1823-7.
15. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
16. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 2003;21:4112-9.
17. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
18. Jordan K: Neurokinin-1 receptor antagonists: a new approach in antiemetic therapy. Onkologie 2006;29:39-43.
19. De Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ: Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11.
20. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300.